<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30810668</article-id><article-id pub-id-type="pmc">6385832</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2019-0600</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>"Vasopressor Support Sparing Strategies": a Concept to be
Incorporated as a Paradigm in the Treatment of Vasodilatory
Shock</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9631-946X</contrib-id><name><surname>Evora</surname><given-names>Paulo Roberto B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7704-2258</contrib-id><name><surname>Braile</surname><given-names>Domingo M.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3"/><role>MD, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Editor-in-Chief Interim - BJCVS Faculdade de Medicina de
Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo (FMRP-USP),
Ribeir&#x000e3;o Preto, SP, Brazil. </aff><aff id="aff2">
<label>2</label> Editor-in-Chief - BJCVS Faculdade de Medicina de S&#x000e3;o
Jos&#x000e9; do Rio Preto (FAMERP), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil
and Universidade de Campinas (UNICAMP), Campinas, SP, Brazil. </aff><aff id="aff3">
</aff><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>I</fpage><lpage>II</lpage><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions></article-meta></front><body><sec><title>The BJCVS Highlight</title><p>Unacceptably high rates of mortality in critically ill patients, including those
under cardiopulmonary bypass (CPB), are a reality that keeps itself through time,
despite advances in pharmacology and technology. Shock treatment initiated with
fluid resuscitation strategies and administration of adrenergic vasopressor agents
in nonresponsive patients to restore arterial pressure and protect the
microcirculation. High catecholamine (norepinephrine) dosing requirements are
necessary to achieve targeted hemodynamic goals, increasing the risk of
vasopressor-induced adverse events. In addition, catecholamines are associated with
well-known side effects, including increased myocardial oxygen consumption and
development of arrhythmias, which are two compromising conditions of good evolution
even of elective cardiac surgeries<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>Catecholamines are predominantly used in supraphysiological doses to overcome the
consequences of pathological inflammatory shock. However, these adrenergic agents
cause direct organ damage and have multiple harmful biological effects on immune,
metabolic and coagulation pathways, with negatively patient outcomes. Andreis &#x00026;
Singer<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>
appropriately called this situation "the schizophrenic 'Jekyll-and-Hyde'
catecholamines characteristics in critical illness", as they are both necessary for
survival although detrimental in excess. It is clear that this Jekyll-and-Hyde drama
was based on the microcirculatory detrimental of high and prolonged use of
catecholamines. Therefore, it is imperative to find ways of protecting
microcirculation against the deleterious effects of catecholamines, justifying the
motivation of this Editorial about "Vasopressor Support Sparing Strategies" as a
concept to be incorporated as a paradigm in the treatment of vasodilatory
shock<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>Few randomized studies exist to guide clinical management and hemodynamic
stabilization in patients who do not respond to the standard approach (fluid
resuscitation and norepinephrine). Many adjuvant therapies, such as hydrocortisone
(high doses used in the 1970's), thiamine and ascorbic acid, have been suggested to
increase blood pressure in severe shock and should be considered when combined
vasopressor therapy is needed<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Nowadays, vasopressin and methylene blue seems
to be the most commonly used drugs as on option for association with high doses of
norepinephrine (NE). Vasopressin acts through membrane receptors and methylene, by
blocking the NO/cGMP pathway, "crosstalking with the amine-dependent PGI2/cAMP
pathway"<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>Based on almost 25 years of experimental and clinical experience our opinion is that
methylene blue (MB), at present, may be the best, safest, and cheapest option. Even
in the absence of definitive multicentric studies, experimental studies suggest a
potential protective role of MB in microcirculation. In an experimentally-induced
septic shock model in rats, only the combination of NE + MB restored mean arterial
pressure to control levels by the end of the three-hour
experiment<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Finally, the current concept should be illustrated by the above mentioned
"Jekyll-and-Hyde" analogy. Some remarks should be mentioned based on the
"Vasopressor Support Sparing Strategies" paradigm:</p><p>
<list list-type="order"><list-item><p>What is the best drug considering the pharmacological mechanism (membrane
receptors, endothelium-dependent mechanisms...)?</p></list-item><list-item><p>Precocious "window of opportunity" or even always adopt the support
sparing strategies?</p></list-item><list-item><p>Search for novel vasopressor agents, such as synthetic human angiotensin
II, which would increase blood pressure and reduce the need for high
doses of catecholamine vasopressors.</p></list-item><list-item><p>Optimistically, if possible, seek new vasopressors that increase the
arterial blood pressure without microcirculatory damage.</p></list-item></list>
</p><p>There are few effective rescue therapies for established refractory shock, which
emphasizes the importance of aggressive intervention before refractory shock
develops, including earlier initiation of rational combination vasopressor
therapy.</p></sec><sec><title>Articles in this Issue</title><p>This issue of BJCVS presents a blind peer-reviewed selection of 20 papers that were
selected by order of acceptance: 11 original papers, 2 review articles, 1 special
article, 2 multimedia and 4 selected case reports. In response to our editorial
efforts, two Letters to the Editor have been included in this issue.</p></sec><sig-block><sig><bold>Paulo Roberto B. Evora</bold><break/> https://orcid.org/0000-0001-9631-946X<break/><sup>1</sup>Editor-in-Chief Interim - BJCVS<break/> Faculdade de Medicina de
Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo (FMRP-USP),
Ribeir&#x000e3;o Preto, SP, Brazil.</sig><sig><bold>Domingo M. Braile</bold><break/> https://orcid.org/0000-0001-7704-2258<break/><sup>2</sup>Editor-in-Chief - BJCVS<break/> Faculdade de Medicina de S&#x000e3;o
Jos&#x000e9; do Rio Preto (FAMERP), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil
and Universidade de Campinas (UNICAMP), Campinas, SP, Brazil.</sig></sig-block></body><back><ack><title>Acknowledgment</title><p>We would like to express our gratitude to all the BJCVS authors, reviewers, and
associate editors who keep hard working to raise the level of this publication.
Special acknowledgment to Luis Fernando Kubrusly for the additional editorial.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>MS</given-names></name><name><surname>Barletta</surname><given-names>JF</given-names></name><name><surname>Smithburger</surname><given-names>PL</given-names></name><name><surname>Radosevich</surname><given-names>JJ</given-names></name><name><surname>Kane-Gill</surname><given-names>SL</given-names></name></person-group><article-title>Catecholamine vasopressor support sparing strategies in
vasodilatory shock</article-title><source>Pharmacotherapy</source><day>01</day><month>12</month><year>2018</year><pub-id pub-id-type="doi">10.1002/phar.2199</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreis</surname><given-names>DT</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name></person-group><article-title>Catecholamines for inflammatory shock: a Jekyll-and-Hyde
conundrum</article-title><source>Intensive Care Med</source><year>2016</year><volume>42</volume><issue>9</issue><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">26873833</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jentzer</surname><given-names>JC</given-names></name><name><surname>Vallabhajosyula</surname><given-names>S</given-names></name><name><surname>Khanna</surname><given-names>AK</given-names></name><name><surname>Chawla</surname><given-names>LS</given-names></name><name><surname>Busse</surname><given-names>LW</given-names></name><name><surname>Kashani</surname><given-names>KB</given-names></name></person-group><article-title>Management of refractory vasodilatory shock</article-title><source>Chest</source><year>2018</year><volume>154</volume><issue>2</issue><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">29329694</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Viaro</surname><given-names>F</given-names></name></person-group><article-title>The guanylyl cyclase inhibition by MB as vasoplegic circulatory
shock therapeutical target</article-title><source>Curr Drug Targets</source><year>2006</year><volume>7</volume><issue>9</issue><fpage>1195</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">17017895</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Celotto</surname><given-names>AC</given-names></name></person-group><article-title>"Methylene blue should be relegated to rescue use and not as
first-line therapy" cannot become a paradigm</article-title><source>J Cardiothorac Vasc Anesth</source><year>2014</year><volume>28</volume><issue>2</issue><fpage>e11</fpage><lpage>e12</lpage><pub-id pub-id-type="pmid">24295723</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nantais</surname><given-names>J</given-names></name><name><surname>Dumbarton</surname><given-names>TC</given-names></name><name><surname>Farah</surname><given-names>N</given-names></name><name><surname>Maxan</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Minor</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of methylene blue in addition to norepinephrine on the
intestinal microcirculation in experimental septic shock</article-title><source>Clin Hemorheol Microcirc</source><year>2014</year><volume>58</volume><issue>1</issue><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">25227191</pub-id></element-citation></ref></ref-list></back></article>